Five Ebola research projects, including a large-scale clinical trial of a potential vaccine, will receive EUR 24.4 million funding as the European Commission activates an emergency fast-track procedure that enables it to release research cash in urgent situations, such as an epidemic.
Researchers have discovered how soluble proteins produced by the Ebola virus cause damage to blood vessel walls and contribute to the internal bleeding characteristic of the disease, opening up a new avenue for possible treatment.
Internet of Things and social inclusion enterprises also recognised.
Expert networks have sprung into action to contain the disease.
The European Commission has launched plans for the next research funding programme.